OUTLOOK THERAPEUTICS, INC. Stock-Based Compensation
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Stock-Based Compensation of $2.43 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $791.67K, a 52.94% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $757.48K, a 56.03% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $881.15K, a 76.01% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.82M, a 29.51% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $8.90M, a 65.23% increase from fiscal 2024.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $5.39M, a 2.92% decline from fiscal 2023.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $5.55M, a 28.06% decline from fiscal 2022.
- OUTLOOK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $7.71M, a 57.77% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $791.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-18 | $1.55M derived: sum of 2 quarters · filed 2026-08-18 | $2.43M 10-Q · filed 2026-08-18 | $4.25M derived: sum of 4 quarters · filed 2026-08-18 |
| 2026-03-31 | $757.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $1.64M 10-Q · filed 2026-05-15 | $3.46M derived: sum of 3 quarters · filed 2026-05-15 | $5.14M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-12-31 | $881.15K 10-Q · filed 2026-02-17 | $2.70M derived: sum of 2 quarters · filed 2026-02-17 | $4.38M derived: sum of 3 quarters · filed 2026-08-18 | $6.11M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-09-30 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $3.50M derived: sum of 2 quarters · filed 2026-08-18 | $5.23M derived: sum of 3 quarters · filed 2026-08-18 | $8.90M 10-K · filed 2025-12-19 |
| 2025-06-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-18 | $3.40M derived: sum of 2 quarters · filed 2026-08-18 | $7.08M 10-Q · filed 2026-08-18 | $8.48M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-03-31 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $5.40M 10-Q · filed 2026-05-15 | $6.80M derived: sum of 3 quarters · filed 2026-05-15 | $8.20M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.67M 10-Q · filed 2026-02-17 | $5.08M derived: sum of 2 quarters · filed 2026-02-17 | $6.47M derived: sum of 3 quarters · filed 2026-02-17 | $7.78M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $2.80M derived: sum of 2 quarters · filed 2025-12-19 | $4.11M derived: sum of 3 quarters · filed 2025-12-19 | $5.39M 10-K · filed 2025-12-19 |
| 2024-06-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-14 | $2.71M derived: sum of 2 quarters · filed 2025-08-14 | $3.98M 10-Q · filed 2025-08-14 | $5.37M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-15 | $2.58M 10-Q · filed 2025-05-15 | $3.97M derived: sum of 3 quarters · filed 2025-05-15 | $5.35M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.27M 10-Q · filed 2025-02-14 | $2.66M derived: sum of 2 quarters · filed 2025-02-14 | $4.04M derived: sum of 3 quarters · filed 2025-02-14 | $5.43M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $2.77M derived: sum of 2 quarters · filed 2024-12-27 | $4.15M derived: sum of 3 quarters · filed 2024-12-27 | $5.55M 10-K · filed 2024-12-27 |
| 2023-06-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-14 | $2.77M derived: sum of 2 quarters · filed 2024-08-14 | $4.16M 10-Q · filed 2024-08-14 | $5.53M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-15 | $2.78M 10-Q · filed 2024-05-15 | $4.15M derived: sum of 3 quarters · filed 2024-05-15 | $5.52M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.39M 10-Q · filed 2024-02-14 | $2.77M derived: sum of 2 quarters · filed 2024-02-14 | $4.14M derived: sum of 3 quarters · filed 2024-02-14 | $7.90M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-22 | $2.74M derived: sum of 2 quarters · filed 2023-12-22 | $6.51M derived: sum of 3 quarters · filed 2023-12-22 | $7.71M 10-K · filed 2023-12-22 |
| 2022-06-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $5.13M derived: sum of 2 quarters · filed 2023-08-14 | $6.33M 10-Q · filed 2023-08-14 | $7.74M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $3.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-15 | $4.97M 10-Q · filed 2023-05-15 | $6.37M derived: sum of 3 quarters · filed 2023-05-15 | $7.57M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.20M 10-Q · filed 2023-02-14 | $2.61M derived: sum of 2 quarters · filed 2023-02-14 | $3.81M derived: sum of 3 quarters · filed 2023-02-14 | $4.94M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-09-30 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-29 | $2.60M derived: sum of 2 quarters · filed 2022-12-29 | $3.73M derived: sum of 3 quarters · filed 2022-12-29 | $4.89M 10-K · filed 2022-12-29 |
| 2021-06-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-10 | $2.33M derived: sum of 2 quarters · filed 2022-08-10 | $3.48M 10-Q · filed 2022-08-10 | $4.27M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-13 | $2.28M 10-Q · filed 2022-05-13 | $3.07M derived: sum of 3 quarters · filed 2022-05-13 | $4.43M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $1.15M 10-Q · filed 2022-02-14 | $1.94M derived: sum of 2 quarters · filed 2022-02-14 | $3.30M derived: sum of 3 quarters · filed 2022-02-14 | $3.60M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $784.69K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | $2.14M derived: sum of 2 quarters · filed 2021-12-23 | $2.45M derived: sum of 3 quarters · filed 2021-12-23 | $2.81M 10-K · filed 2021-12-23 |
| 2020-06-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | $1.66M derived: sum of 2 quarters · filed 2021-08-13 | $2.02M 10-Q · filed 2021-08-13 | $2.23M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $304.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-14 | $664.02K 10-Q · filed 2021-05-14 | $868.59K derived: sum of 3 quarters · filed 2021-05-14 | $837.32K derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $359.48K 10-Q · filed 2021-02-16 | $564.05K derived: sum of 2 quarters · filed 2021-02-16 | $532.78K derived: sum of 3 quarters · filed 2021-02-16 | $800.52K derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-09-30 | $204.57K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | $173.30K derived: sum of 2 quarters · filed 2020-12-23 | $441.05K derived: sum of 3 quarters · filed 2020-12-23 | $1.31M 10-K · filed 2020-12-23 |
| 2019-06-30 | -$31.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-14 | $236.48K derived: sum of 2 quarters · filed 2020-08-14 | $1.11M 10-Q · filed 2020-08-14 | $1.27M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $267.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-15 | $1.14M 10-Q · filed 2020-05-15 | $1.30M derived: sum of 3 quarters · filed 2020-05-15 | $1.54M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $872.29K 10-Q · filed 2020-02-14 | $1.03M derived: sum of 2 quarters · filed 2020-02-14 | $1.27M derived: sum of 3 quarters · filed 2020-02-14 | $968.34K derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-09-30 | $162.14K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | $396.26K derived: sum of 2 quarters · filed 2019-12-19 | $96.05K derived: sum of 3 quarters · filed 2019-12-19 | $1.99M 10-K · filed 2019-12-19 |
| 2018-06-30 | $234.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | -$66.09K derived: sum of 2 quarters · filed 2019-08-14 | $1.82M 10-Q · filed 2019-08-14 | $3.48M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$300.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15 | $1.59M 10-Q · filed 2019-05-15 | $3.25M derived: sum of 3 quarters · filed 2019-05-15 | $5.37M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $1.89M 10-Q · filed 2019-02-14 | $3.55M derived: sum of 2 quarters · filed 2019-02-14 | $5.67M derived: sum of 3 quarters · filed 2019-02-14 | $8.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-09-30 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | $3.78M derived: sum of 2 quarters · filed 2018-12-18 | $6.11M derived: sum of 3 quarters · filed 2018-12-18 | $8.57M 10-K · filed 2018-12-18 |
| 2017-06-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | $4.45M derived: sum of 2 quarters · filed 2018-08-14 | $6.91M 10-Q · filed 2018-08-14 | $10.74M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | $4.79M 10-Q · filed 2018-05-15 | $8.62M derived: sum of 3 quarters · filed 2018-05-15 | $19.20M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $2.46M 10-Q · filed 2018-02-14 | $6.30M derived: sum of 2 quarters · filed 2018-02-14 | $16.87M derived: sum of 3 quarters · filed 2018-02-14 | $12.42M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-09-30 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | $14.41M derived: sum of 2 quarters · filed 2017-12-29 | $9.96M derived: sum of 3 quarters · filed 2017-12-29 | $12.45M 10-K · filed 2017-12-29 |
| 2016-06-30 | $10.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-14 | $6.13M derived: sum of 2 quarters · filed 2017-08-14 | $8.62M 10-Q · filed 2017-08-14 | $10.59M derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | -$4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-15 | -$1.96M 10-Q · filed 2017-05-15 | $14.84K derived: sum of 3 quarters · filed 2017-05-15 | $2.05M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | $2.49M 10-Q · filed 2017-02-14 | $4.46M derived: sum of 2 quarters · filed 2017-02-14 | $6.49M derived: sum of 3 quarters · filed 2017-02-14 | |
| 2015-09-30 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-29 | $4.00M derived: sum of 2 quarters · filed 2016-12-29 | $11.18M 10-K · filed 2016-12-29 | |
| 2015-06-30 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-15 | $9.21M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $7.18M 10-Q · filed 2016-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |